Popular Articles From: Platinum Group Metals Updates the Waterberg Joint Venture and Waterberg Extension Projects to Patterson Companies Announces 2014 Analyst and Investor Day


http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0974143001&sourceType=1 http://www.ccnmatthews.com/logos/20070906-ptm1.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Platinum Group Metals Updates the Waterberg Joint Venture and Waterberg Extension Projects investment picks
Plains All American Pipeline, L.P. (NYSE: PAA ) announced today that it plans to construct a new 16-inch, 226-mile pipeline originating from the Plains Basin pipeline system at Duncan, Okla.
Sign-up for Plains All American Pipeline Announces New Pipeline from Duncan, Okla. to Longview, Texas investment picks
Pioneer Natural Resources Company (NYSE:PXD) (“Pioneer” or “the Company”) today announced that the Company is pursuing the divestment of its 50.1% share of the Eagle Ford Shale Midstream business (“EFS Midstream”). Reliance Holding USA, Inc. (“Reliance”) owns the remaining 49.9% of the EFS Midstream business and also plans to pursue the divestment of its share in a joint process with Pioneer.
Sign-up for Pioneer Natural Resources Pursuing Divestment of Eagle Ford Shale Midstream Business investment picks
Pioneer Natural Resources Company (NYSE:PXD) (“Pioneer” or the “Company”) today announced that it has priced a public offering of 5,750,000 shares of its common stock for proceeds of approximately $1 billion.
Sign-up for Pioneer Natural Resources Company Announces Pricing of Common Stock Offering investment picks
Pinnacle West Capital Corporation’s (NYSE: PNW) Board of Directors voted today to raise the Company’s dividend by 4.85 percent, or 11 cents per common share annually.
Sign-up for Pinnacle West Increases Quarterly Dividend investment picks
GREELEY, Colo., Sept.
Sign-up for Pilgrim's Pride Corporation to Host 2014 Third Quarter Earnings Call on Oct. 30, 2014 investment picks
Pier 1 Imports, Inc. (NYSE:PIR) today reported financial results for the second quarter ended August 30, 2014.
Sign-up for Pier 1 Imports, Inc. Reports Fiscal 2015 Second Quarter Results; Revises Full Year Financial Guidance; Provides Roadmap for Omni-Channel Business and Intermediate-Term Financial Goals investment picks
North Carolina Utilities Commission approves Company's affiliate agreements with proposed Atlantic Coast Pipeline CHARLOTTE, N.C. , Oct.
Sign-up for Piedmont Natural Gas Receives Regulatory Approval for Atlantic Coast Pipeline Agreements investment picks
Physicians Realty Trust (NYSE:DOC) (the “Company”), a self-managed healthcare properties REIT, announced today the partial closing of the 309,865 square foot Columbus Regional Medical Office Portfolio (the “Portfolio”) which includes thirteen medical office buildings, twelve of which are located in Columbus, Georgia and one in Phenix City, Alabama.
Sign-up for Physicians Realty Trust Announces $123.2 Million in Acquisitions and Anticipated Acquisitions investment picks
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that results from a double-blind, placebo-controlled, multicenter phase II trial of GED-0301 in 166 patients with active Crohn's disease will be presented at the United European Gastroenterology Week in Vienna, Austria.
Sign-up for Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced results from CheckMate -063, a Phase 2 single-arm, open-label study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, administered as a single agent in patients with advanced squamous cell non-small cell lung cancer (NSCLC) who have progressed after at least two prior systemic treatments with 65% receiving three or more prior therapies (n=117). With approximately 11 months of minimum follow up, the objective response rate (ORR, the study’s primary endpoint) was 15% (95% CI = 8.7, 22.2) as assessed by an independent review committee (IRC) using RECIST 1.1 criteria and the median duration of response was not reached.
Sign-up for Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology investment picks
PharMerica Corporation (NYSE:PMC), a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, today announced that it has completed the acquisition of Millennium Pharmacy Systems (“Millennium”). Millennium is a pharmacy services provider to the long-term care industry that operates seven institutional pharmacies primarily in the Mid-Atlantic region.
Sign-up for PharMerica Acquires Millennium Pharmacy Systems investment picks
Prestigious international competition tests safety and technical skills among more than 200 elite teams from the United States, Canada and the United Kingdom GRASS VALLEY, Calif.
Sign-up for PG&E Team Wins Championship Honors In 2014 International Lineman's Rodeo investment picks
SAN FRANCISCO , Oct.
Sign-up for PG&E Self-Reports Additional Emails To CPUC investment picks
Pfizer Inc. announced today that it will present data for several of its marketed and investigational medicines for inflammatory and immunological conditions at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2014 Annual Meeting (November 14-19, Boston, Massachusetts). Twenty-one abstracts for XELJANZ ® (tofacitinib citrate) will be presented, including the six-year safety and efficacy analyses from long-term extension (LTE) studies and a summary of real-world patient experience, additional post-hoc analyses from the clinical development program, and health and economics outcomes research, adding to the substantial body of evidence for XELJANZ as an oral treatment option for moderate to severe rheumatoid arthritis (RA). Data will also be presented for several additional Pfizer assets, including PF-04236921, an investigational
Sign-up for Pfizer Highlights Leadership in Rheumatology and Inflammation with Data to be Presented at the ACR/ARHP 2014 Annual Meeting investment picks
Pfizer Inc. (NYSE:PFE) announced today that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, to jointly develop and commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck KGaA as a potential treatment for multiple types of cancer.
Sign-up for Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology investment picks
http://media.marketwire.com/attachments/201406/258111_Performancelogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1161043&ProfileId=051205&sourceType=1 EXETER, NH --
Sign-up for Performance Sports Group Addresses Pending NOCSAE Lacrosse Notification investment picks
New research in the international medical journal CHEST showed patients had reduced hospital stays, medical costs and returns to the hospital ABBOTT PARK, Ill., Nov.
Sign-up for People with Chronic Obstructive Pulmonary Disease (COPD) Who Received Nutrition Treatment in the Hospital Had Better Health Outcomes investment picks
Estimated Annual Incremental Earnings per Share of $0.12 to $0.14 BLOOMFIELD HILLS, Mich.
Sign-up for Penske Automotive Completes Acquisition Of Heavy-Duty Truck Dealership Group investment picks
Successful Appeal of the Tincher Ruling is the Company's Fifth Consecutive Legal Victory MIDDLETOWN, Conn., Dec.
Sign-up for Pennsylvania Supreme Court Rules in Favor of Omega Flex in Striking Down the State's Broad Liability Law and Vacating the Jury's Ruling in the Tincher Case investment picks
http://media.marketwire.com/attachments/201410/81087_PegaLogoBLACKCYAN_resize2.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1154751&ProfileId=051205&sourceType=1 CAMBRIDGE, MA --
Sign-up for Pegasystems Raises the Bar for Customer Experience With Latest Industry-Leading Customer Service Application investment picks
Pebblebrook Hotel Trust (the “Company”) (NYSE: PEB) announced today that it intends to issue 3,200,000 of its common shares of beneficial interest, $0.01 par value per share, in an underwritten public offering.
Sign-up for Pebblebrook Hotel Trust Announces Public Offering of 3,200,000 Common Shares investment picks
Pebblebrook Hotel Trust (NYSE:PEB) (the “Company”) today announced that it has acquired The Westin Colonnade Coral Gables (“The Westin Colonnade”) for $59.4 million.
Sign-up for Pebblebrook Hotel Trust Acquires The Westin Colonnade Coral Gables in Miami, Florida investment picks
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today reported that the U.S. Food and Drug Administration (FDA) has extended the company’s Prescription Drug User Fee Act (PDUFA) action date for its Natpara Biologics License Application (BLA) by three months from October 24, 2014 to January 24, 2015.
Sign-up for PDUFA Action Date for Natpara® BLA Extended Three Months to January 24, 2015 investment picks
SAN JOSE, Calif., Oct.
Sign-up for PDF Solutions(R) Reports Third Fiscal Quarter 2014 Results investment picks
Paycom Software, Inc. (“Paycom”) (NYSE: PAYC), a leading provider of a comprehensive cloud-based human capital management software solution, today announced its financial results for the quarter ended September 30, 2014.
Sign-up for Paycom Software Reports Third Quarter 2014 Earnings investment picks
Patterson Companies (Nasdaq: PDCO) today announced that it will host its 2014 Analyst and Investor Day on Wednesday, October 1, from 7:30 a.m. to 12 p.m. ET.
Sign-up for Patterson Companies Announces 2014 Analyst and Investor Day investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Popular Articles From: Platinum Group Metals Updates the Waterberg Joint Venture and Waterberg Extension Projects to Patterson Companies Announces 2014 Analyst and Investor Day
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent